Advertisement

Drugs

, Volume 56, Issue 2, pp 241–249 | Cite as

Orlistat

  • Wendy McNeely
  • Paul Benfield
Adis New Drug Profile

Abstract

  • ▴ Orlistat (tetrahydrolipstatin) is an inhibitor of pancreatic and other lipases. As a pancreatic lipase inhibitor, it acts in the gastrointestinal lumen and is indicated for use in obesity.

  • ▴ Serum total cholesterol and low density lipoprotein-cholesterol levels were reduced in obese, but otherwise healthy, patients during ≤2 years' orlistat treatment; serum triglyceride and high density and very low density lipoprotein-cholesterol levels were unchanged in trials of ≤12 weeks.

  • ▴ Obese patients who were maintained on a hypocaloric diet and who received orlistat 360 mg/day for 12 weeks lost a significantly greater percentage of bodyweight than placebo recipients (5 vs 3.5%).

  • ▴ In 2-year studies, weight loss was significantly greater in orlistat than in placebo recipients by the end of year 1; weight was further reduced or maintained in the second year, when a eucaloric diet was allowed, in orlistat but not placebo recipients.

  • ▴ A greater proportion of orlistat than placebo recipients lost >5% or >10% of their initial bodyweight in 1- and 2-year studies.

Keywords

Adis International Limited Placebo Recipient Orlistat Lipase Inhibitor Orlistat Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Obesity: advances in understanding and treatment. Drug Mark Dev 1995 May 22; 6: 26–41Google Scholar
  2. 2.
    Beales PL, Kopelman PG. Options for the management of obesity. PharmacoEconomics 1994; 5 Suppl. 1: 18–32PubMedCrossRefGoogle Scholar
  3. 3.
    National Task Force on Obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996 Dec 18; 276(23): 1907–15CrossRefGoogle Scholar
  4. 4.
    Pisunyer. Guidelines for the approval and use of drugs to treat obesity — a position paper of the North American Association for the Study of Obesity. Obes Res 1995 Sep; 3: 473–8Google Scholar
  5. 5.
    Atkinson RL, Blank RC, Loper JF, et al. Combined drug treatment of obesity. Obes Res 1995 Nov; 3 Suppl. 4: 497–500Google Scholar
  6. 6.
    Borgstrom B. Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin [in English]. Biochim Biophys Acta 1988 Oct 14; 962: 308–16PubMedCrossRefGoogle Scholar
  7. 7.
    Weibel EK, Hadvary P, Hochuli E, et al. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity [in English]. J Antibiot Tokyo 1987 Aug; 40: 1081–5Google Scholar
  8. 8.
    Hadvary P, Lengsfeld H, Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin [in English]. Biochem J 1988 Dec 1; 256: 357–61PubMedGoogle Scholar
  9. 9.
    Zhi J, Melia AT, Eggers H, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995 Nov; 35: 1103–8PubMedGoogle Scholar
  10. 10.
    Hauptman JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor ro-18-0647 (tetrahydrolipstatin). Am J Clin Nutr 1992 Jan; 55 Suppl.: 309–13Google Scholar
  11. 11.
    Güzelhan G, Odink J, Niestijl JJ, et al. Influence of dietary composition on the inhibition of fat absorption by orlistat. J Int Med Res 1994 Sep–Oct; 22: 255–65PubMedGoogle Scholar
  12. 12.
    Hartmann D, Hussain Y, Güzelhan C, et al. Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake. Br J Clin Pharmacol 1993 Sep; 36: 266–70PubMedCrossRefGoogle Scholar
  13. 13.
    Tonstad S, Pometta D, Erkelens DW, et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 1994; 46(5): 405–10PubMedCrossRefGoogle Scholar
  14. 14.
    Reitsma JB, Cabezas MC, Debruin TWA, et al. Relationship between improved postprandial lipemia and low-density lipo-protein metabolism during treatment with tetrahydrolipstatin, apancreatic lipase inhibitor. Metabolism 1994 Mar; 43: 293–8PubMedCrossRefGoogle Scholar
  15. 15.
    Drent ML, Larsson I, Williamolsson T, et al. Orlistat (RO 180647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes 1995 Apr; 19: 221–6Google Scholar
  16. 16.
    Lucas C. A 2-year placebo-controlled study of orlistat in the treatment of obesity [abstract no. 0339]. Diabetes 1997 May; 46 Suppl. 1: 86AGoogle Scholar
  17. 17.
    Rissanen A. Long-term weight management in obesity with orlistat, a new gastrointestinal lipase inhibitor [abstract no. 0342]. Diabetes 1997 May; 46 Suppl. 1: 87ACrossRefGoogle Scholar
  18. 18.
    Noack R. Two-year study of orlistat in the treatment of obesity [abstract]. 79th Annual meeting of the American Endocrine Society (June 1997)Google Scholar
  19. 19.
    Drent ML, Popp-Snijders C, Ader HJ, et al. Lipase inhibition and hormonal status, body composition and gastrointestinal processing of a liquid high-fat mixed meal in moderately obese subjects [in English]. Obes Res 1995 Nov; 3: 573–81PubMedGoogle Scholar
  20. 20.
    Froehlich F, Hartmann D, Guezelhan C, et al. Influence of orlistat on the regulation of gallbladder contraction in man: a randomized double-blind placebo-controlled crossover study. Dig Dis Sci 1996 Dec; 41: 2404–8PubMedCrossRefGoogle Scholar
  21. 21.
    Melia AT, Zhi J, Koss-Twardy SG, et al. The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 1995 Aug; 35: 840–3PubMedGoogle Scholar
  22. 22.
    Melia AT, Mulligan TE, Zhi J. Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers. J Clin Pharmacol 1996 Apr; 36: 352–5PubMedGoogle Scholar
  23. 23.
    Melia AT, Mulligan TE, Zhi J. The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. J Clin Pharmacol 1996 Jul; 36: 654–8PubMedGoogle Scholar
  24. 24.
    Zhi J, Melia AT, Koss-Twardy SG, et al. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. J Clin Pharmacol 1995 May; 35: 521–5PubMedGoogle Scholar
  25. 25.
    Zhi J, Melia AT, Guerciolini R, et al. The effect of tetrahydrolipstatin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1996 Jul; 36: 659–66PubMedGoogle Scholar
  26. 26.
    Weber C, Tam YK, Schmidtke-Schrezenmeier G. Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers. Eur J Clin Pharmacol 1996 Sep; 51: 87–90PubMedCrossRefGoogle Scholar
  27. 27.
    Hartmann D, Güzelhan C, Zuiderwijk PBM. Lack of interaction between orlistat and oral contraceptives. Eur J Clin Pharmacol 1996 Jul; 50: 421–4PubMedCrossRefGoogle Scholar
  28. 28.
    Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 1996 Jul; 36: 647–53PubMedGoogle Scholar
  29. 29.
    Zhi J, Melia AT, Koss-Twardy SG, et al. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. J Clin Pharmacol 1996 Feb; 36: 152–9PubMedGoogle Scholar
  30. 30.
    Canovatchel W. Long-term tolerability profile of orlistat, an intestinal lipase inhibitor [abstract]. F. Hoffmann-La Roche (New Jersey). 1997 (Data on file). Presented at the 16th IDF Congress, Helsinki, 1997Google Scholar
  31. 31.
    Van Gaal LF, Broom JI, Enzi G, et al. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur J Pharmacol 1998; 54: 125–32CrossRefGoogle Scholar
  32. 32.
    Hollander P. A 57-week study of orlistat in the treatment of obese patients with NIDDM [abstract no. 0213]. Diabetes 1997 May; 46 Suppl. 1: 55AGoogle Scholar
  33. 33.
    Roche 1998. Xenical® (orlistat) Advisory Committee briefing document. Presented at the Advisory Committee. 1998 Mar 13Google Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  1. 1.Adis International LimitedMairangi Bay, Auckland 10New Zealand

Personalised recommendations